this post was submitted on 22 Jun 2025
7 points (100.0% liked)

Futurology

2899 readers
54 users here now

founded 2 years ago
MODERATORS
voidx@futurology.today
Lugh@futurology.today
Espiritdescali@futurology.today
AwesomeLowlander@futurology.today
7
Verve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. (investor.lilly.com)
submitted 6 days ago by Lugh@futurology.today to c/futurology@futurology.today
0 comments fedilink hide all child comments
no comments (yet)
sorted by: hot top controversial new old
there doesn't seem to be anything here